242 related articles for article (PubMed ID: 21312256)
1. Flow cytometric platelet cross-matching to predict platelet transfusion in acute leukemia.
Sayed D; Bakry R; El-Sharkawy N; Zahran A; Khalaf MR
J Clin Apher; 2011; 26(1):23-8. PubMed ID: 21312256
[TBL] [Abstract][Full Text] [Related]
2. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
3. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
4. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
5. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
6. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
Menitove JE; Duquesnoy RJ
Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
[TBL] [Abstract][Full Text] [Related]
7. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J
Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382
[TBL] [Abstract][Full Text] [Related]
8. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
McVey M; Cserti-Gazdewich CM
Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
[TBL] [Abstract][Full Text] [Related]
9. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
[TBL] [Abstract][Full Text] [Related]
10. Flow Cytometric Panel-Reactive Antibody Results and the Ability to Find Transfusion-Compatible Platelets after Antibody-Desensitization for Allogeneic Bone Marrow Transplant.
Rosenbaum ER; Pandey S; Harville TO; Drobena GA; Cottler-Fox M
Ann Clin Lab Sci; 2016 Dec; 46(6):662-665. PubMed ID: 27993881
[TBL] [Abstract][Full Text] [Related]
11. The alloimmunized patient: effective transfusion support and newer experimental approaches.
Pamphilon DH
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
[TBL] [Abstract][Full Text] [Related]
12. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.
Beligaswatte A; Tsiopelas E; Humphreys I; Bennett G; Robinson K; Davis K; Bardy P
Br J Haematol; 2013 Aug; 162(3):409-12. PubMed ID: 23651440
[TBL] [Abstract][Full Text] [Related]
13. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
Levy L; Woodfield DG
N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
[TBL] [Abstract][Full Text] [Related]
14. [Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites].
Panzer S; Maier F; Höcker P; Mayr WR; Hinterberger W
Infusionsther Klin Ernahr; 1987 Apr; 14 Suppl 2():10-4. PubMed ID: 3298059
[TBL] [Abstract][Full Text] [Related]
15. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
16. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
17. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
19. A specific assay for anti-HLA antibodies: application to platelet donor selection.
Millard FE; Tani P; McMillan R
Blood; 1987 Nov; 70(5):1495-9. PubMed ID: 3311206
[TBL] [Abstract][Full Text] [Related]
20. [Thrombocyte substitution in acute leukemia. Effect of histocompatibility on the clinical efficacy].
Kubel M; Freistedt B; Hammer P; Thierbach V; Helbig W; Haustein B; Schultze W
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):355-64. PubMed ID: 6179839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
